Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
3D cellular model
Ascites
Biomarkers
Epithelial-to-mesenchymal transition
Functional assay
High-grade serous ovarian cancer
PARP inhibitors homologous recombination repair pathway
Primary cell cultures
Spheroids
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
19 11 2020
19 11 2020
Historique:
received:
30
05
2020
accepted:
06
11
2020
entrez:
20
11
2020
pubmed:
21
11
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Poly(ADP-ribose) polymerase inhibitors (PARPis) specifically target homologous recombination deficiency (HRD) cells and display good therapeutic effect in women with advanced-stage BRCA1/2-mutated breast and epithelial ovarian cancer (EOC). However, about 50% of high grade serous ovarian cancers (HGSOC) present with HRD due to epigenetic BRCA1 inactivation, as well as genetic/epigenetic inactivation(s) of other HR genes, a feature known as "BRCAness". Therefore, there is a potential for extending the use of PARPis to these patients if HR status can be identified. We have developed a 3D (spheroid) functional assay to assess the sensitivity of two PARPis (niraparib and olaparib) in ascites-derived primary cell cultures (AsPCs) from HGSOC patients. A method for AsPCs preparation was established based on a matrix (agarose), allowing for easy isolation and successive propagation of monolayer and 3D AsPCs. Based on this method, we performed cytotoxicity assays on 42 AsPCs grown both as monolayers and spheroids. The response to PARPis treatment in monolayer AsPCs, was significantly higher, compared to 3D AsPCs, as 88% and 52% of the monolayer AsPCs displayed sensitivity to niraparib and olaparib respectively, while 66% of the 3D AsPCs were sensitive to niraparib and 38% to olaparib, the latter being more consistent with previous estimates of HRD (40%-60%) in EOC. Moreover, niraparib displayed a significantly stronger cytotoxic effect in both in 3D and monolayer AsPCs, which was confirmed by consecutive analyses of the HR pathway activity (γH2AX foci formation) in PARPis-sensitive and resistant AsPCs. Global gene expression comparison of 6 PARPi-resistant and 6 PARPi-sensitive 3D AsPCs was indicative for the predominant downregulation of numerous genes and networks with previously demonstrated roles in EOC chemoresistance, suggesting that the PARPis-sensitive AsPCs could display enhanced sensitivity to other chemotherapeutic drugs, commonly applied in cancer management. Microarray data validation identified 24 potential gene biomarkers associated with PARPis sensitivity. The differential expression of 7 selected biomarkers was consecutively confirmed by immunohistochemistry in matched EOC tumor samples. The application of this assay and the potential biomarkers with possible predictive significance to PARPis therapy of EOC patients now need testing in the setting of a clinical trial.
Sections du résumé
BACKGROUND
Poly(ADP-ribose) polymerase inhibitors (PARPis) specifically target homologous recombination deficiency (HRD) cells and display good therapeutic effect in women with advanced-stage BRCA1/2-mutated breast and epithelial ovarian cancer (EOC). However, about 50% of high grade serous ovarian cancers (HGSOC) present with HRD due to epigenetic BRCA1 inactivation, as well as genetic/epigenetic inactivation(s) of other HR genes, a feature known as "BRCAness". Therefore, there is a potential for extending the use of PARPis to these patients if HR status can be identified.
METHODS
We have developed a 3D (spheroid) functional assay to assess the sensitivity of two PARPis (niraparib and olaparib) in ascites-derived primary cell cultures (AsPCs) from HGSOC patients. A method for AsPCs preparation was established based on a matrix (agarose), allowing for easy isolation and successive propagation of monolayer and 3D AsPCs. Based on this method, we performed cytotoxicity assays on 42 AsPCs grown both as monolayers and spheroids.
RESULTS
The response to PARPis treatment in monolayer AsPCs, was significantly higher, compared to 3D AsPCs, as 88% and 52% of the monolayer AsPCs displayed sensitivity to niraparib and olaparib respectively, while 66% of the 3D AsPCs were sensitive to niraparib and 38% to olaparib, the latter being more consistent with previous estimates of HRD (40%-60%) in EOC. Moreover, niraparib displayed a significantly stronger cytotoxic effect in both in 3D and monolayer AsPCs, which was confirmed by consecutive analyses of the HR pathway activity (γH2AX foci formation) in PARPis-sensitive and resistant AsPCs. Global gene expression comparison of 6 PARPi-resistant and 6 PARPi-sensitive 3D AsPCs was indicative for the predominant downregulation of numerous genes and networks with previously demonstrated roles in EOC chemoresistance, suggesting that the PARPis-sensitive AsPCs could display enhanced sensitivity to other chemotherapeutic drugs, commonly applied in cancer management. Microarray data validation identified 24 potential gene biomarkers associated with PARPis sensitivity. The differential expression of 7 selected biomarkers was consecutively confirmed by immunohistochemistry in matched EOC tumor samples.
CONCLUSION
The application of this assay and the potential biomarkers with possible predictive significance to PARPis therapy of EOC patients now need testing in the setting of a clinical trial.
Identifiants
pubmed: 33213473
doi: 10.1186/s12967-020-02613-4
pii: 10.1186/s12967-020-02613-4
pmc: PMC7678187
doi:
Substances chimiques
Biomarkers
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Adenosine Diphosphate Ribose
20762-30-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
439Subventions
Organisme : CIHR
ID : FDN-388879
Pays : Canada
Références
Am J Physiol Cell Physiol. 2018 Aug 1;315(2):C225-C235
pubmed: 29719173
Nat Rev Cancer. 2004 Oct;4(10):814-9
pubmed: 15510162
Cancers (Basel). 2018 Nov 12;10(11):
pubmed: 30424539
Trends Biochem Sci. 2019 Mar;44(3):226-240
pubmed: 30638972
Int J Cancer. 1997 Jun 20;74(3):275-80
pubmed: 9221804
Sci Rep. 2014 Feb 07;4:4026
pubmed: 24504028
J Endocrinol. 2009 Nov;203(2):191-202
pubmed: 19423641
Cell. 2014 Sep 25;159(1):176-187
pubmed: 25201530
Tumour Biol. 2014 Aug;35(8):7957-64
pubmed: 24833094
BMC Genomics. 2008 Feb 26;9:99
pubmed: 18302766
Cancer Biol Ther. 2019;20(6):843-854
pubmed: 30822218
PLoS One. 2012;7(4):e34279
pubmed: 22509286
Int J Mol Sci. 2019 May 08;20(9):
pubmed: 31071912
J Biomed Biotechnol. 2011;2011:567305
pubmed: 22007144
Sci Rep. 2017 Sep 6;7(1):10741
pubmed: 28878359
Gynecol Oncol. 2008 Feb;108(2):361-9
pubmed: 18073130
Br J Cancer. 2016 Aug 9;115(4):431-41
pubmed: 27415012
Gynecol Oncol. 2019 May;153(2):452-462
pubmed: 30733081
Hum Pathol. 1997 Jun;28(6):734-9
pubmed: 9191009
Clin Cancer Res. 2016 Dec 1;22(23):5651-5660
pubmed: 27678458
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Int J Cancer. 2015 Aug 1;137(3):560-70
pubmed: 25630587
Oncotarget. 2019 Apr 5;10(27):2586-2606
pubmed: 31080552
Clin Cancer Res. 2010 Apr 15;16(8):2344-51
pubmed: 20371688
Nat Commun. 2015 Dec 08;6:8989
pubmed: 26643275
Pharmacol Rep. 2016 Dec;68(6):1225-1229
pubmed: 27668317
Nat Rev Cancer. 2004 Feb;4(2):118-32
pubmed: 14964308
Tumour Biol. 2014 Sep;35(9):9069-78
pubmed: 24913706
J Clin Oncol. 2008 Aug 1;26(22):3785-90
pubmed: 18591545
Oncotarget. 2016 Dec 6;7(49):81645-81660
pubmed: 27835572
Endocr Relat Cancer. 2016 Jun;23(6):R267-85
pubmed: 27226207
Sci Rep. 2017 Oct 16;7(1):13244
pubmed: 29038585
J Cancer Res Clin Oncol. 2019 Feb;145(2):345-361
pubmed: 30448882
Cancer Res. 2016 Nov 1;76(21):6351-6361
pubmed: 27590741
Gynecol Oncol. 2004 Jul;94(1):16-24
pubmed: 15262114
Am J Pathol. 1999 Aug;155(2):343-8
pubmed: 10433927
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Endocr Relat Cancer. 2016 Mar;23(3):147-59
pubmed: 26647384
Nature. 2020 Apr;580(7801):136-141
pubmed: 32238925
J Clin Oncol. 2010 Aug 1;28(22):3570-6
pubmed: 20606085
Cells. 2019 May 25;8(5):
pubmed: 31130643
Cancers (Basel). 2017 Aug 09;9(8):
pubmed: 28792442
Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6500-5
pubmed: 23576741
Cancer Treat Rev. 2019 Feb;73:1-9
pubmed: 30543930
Pathology. 2007 Jun;39(3):305-18
pubmed: 17558857
J Cell Sci. 2017 Jan 1;130(1):203-218
pubmed: 27663511
Anticancer Res. 2014 Feb;34(2):551-6
pubmed: 24510983
Clin Cancer Res. 2014 Feb 1;20(3):764-75
pubmed: 24240112
Biomed Pharmacother. 2020 Mar;123:109661
pubmed: 31931287
Int J Radiat Biol. 2020 May;96(5):651-660
pubmed: 31914341
Clin Exp Pharmacol Physiol. 2017 Jan;44(1):79-87
pubmed: 27658187
Cell Rep. 2016 Jun 14;15(11):2488-99
pubmed: 27264184
Cancers (Basel). 2018 Aug 09;10(8):
pubmed: 30096959
EBioMedicine. 2016 Jun;8:30-39
pubmed: 27428416
Nat Rev Clin Oncol. 2019 Dec;16(12):725-726
pubmed: 31582817
Onco Targets Ther. 2017 Oct 26;10:5195-5208
pubmed: 29138572
Cancer Cell. 2014 Jul 14;26(1):77-91
pubmed: 25026212
Clin Transl Oncol. 2020 Aug;22(8):1240-1251
pubmed: 31939100
J Biol Chem. 2011 Jul 1;286(26):23467-75
pubmed: 21518759
Ann Oncol. 2019 Sep 1;30(9):1437-1447
pubmed: 31218365
Cancer Biol Ther. 2006 Mar;5(3):256-60
pubmed: 16418574
Int J Mol Sci. 2019 Jun 12;20(12):
pubmed: 31212758
Clin Cancer Res. 2019 Sep 1;25(17):5376-5387
pubmed: 31175091
Int J Oncol. 2014 Jul;45(1):129-38
pubmed: 24789349
Lancet Oncol. 2011 Sep;12(9):852-61
pubmed: 21862407
Oncotarget. 2017 Dec 20;9(4):4722-4736
pubmed: 29435137
Cell. 2015 Jan 15;160(1-2):324-38
pubmed: 25557080
Br J Cancer. 2018 Nov;119(11):1401-1409
pubmed: 30353044
PLoS One. 2016 Nov 3;11(11):e0166058
pubmed: 27812204
Mol Diagn Ther. 2016 Jun;20(3):199-212
pubmed: 27139908
Pharmacol Ther. 2018 Aug;188:168-175
pubmed: 29621593
Mol Cancer Ther. 2019 Mar;18(3):642-655
pubmed: 30679390
Cancer Res. 2014 Jan 1;74(1):287-97
pubmed: 24240700
Nat Protoc. 2016 Feb;11(2):347-58
pubmed: 26797458
Sci Rep. 2019 May 9;9(1):7154
pubmed: 31073193
Stem Cell Res. 2018 Oct;32:51-60
pubmed: 30176443
Am J Cancer Res. 2019 Mar 01;9(3):608-618
pubmed: 30949414
J Cell Biochem. 2011 Oct;112(10):2850-64
pubmed: 21618587
Oncogene. 2017 Oct 19;36(42):5840-5851
pubmed: 28628116
Int J Cancer. 1994 Sep 1;58(5):658-62
pubmed: 8077049
Oncology (Williston Park). 2016 Feb;30(2):166-76
pubmed: 26892153
Cancer Discov. 2018 Nov;8(11):1404-1421
pubmed: 30213835
J Cancer. 2018 Sep 8;9(19):3427-3434
pubmed: 30310499
Biomed Res Int. 2014;2014:365867
pubmed: 24804215
Cancer Res. 2007 Feb 15;67(4):1670-9
pubmed: 17308108
N Engl J Med. 2017 Feb 23;376(8):801-2
pubmed: 28225676
Clin Cancer Res. 2017 Dec 1;23(23):7155-7157
pubmed: 28974545
J Ovarian Res. 2019 Nov 8;12(1):105
pubmed: 31703723
PLoS One. 2012;7(10):e48024
pubmed: 23110163
Cancer Control. 2011 Jan;18(1):52-8
pubmed: 21273980
BMC Med Genomics. 2008 Aug 07;1:34
pubmed: 18687136
Histopathology. 2007 May;50(6):773-9
pubmed: 17493241
Oncotarget. 2017 Apr 25;8(17):28575-28587
pubmed: 28212573
Curr Opin Cell Biol. 2005 Oct;17(5):548-58
pubmed: 16098727
Mol Oncol. 2016 Jun;10(6):789-805
pubmed: 26899534
Cancers (Basel). 2019 Jun 17;11(6):
pubmed: 31213009
Nat Med. 2016 Feb;22(2):194-201
pubmed: 26779812
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Oncol Res. 2009;18(2-3):47-56
pubmed: 20066894
Int J Dev Biol. 2004;48(5-6):365-75
pubmed: 15349812
Pharmacol Ther. 2018 Apr;184:201-211
pubmed: 29097309
Oncol Rep. 2013 May;29(5):1721-9
pubmed: 23440494
PLoS Med. 2008 Dec 2;5(12):e232
pubmed: 19053170
J Cell Mol Med. 2019 Apr;23(4):2303-2313
pubmed: 30672100
Cancer Res. 2007 Mar 1;67(5):2030-9
pubmed: 17332331
Cancer Chemother Pharmacol. 2018 Apr;81(4):647-658
pubmed: 29464354
PLoS One. 2012;7(10):e46858
pubmed: 23056490
Br J Cancer. 2008 Apr 22;98(8):1452-6
pubmed: 18414472
J Cell Physiol. 2018 Jun;233(6):4546-4562
pubmed: 29152737
Int J Gynecol Pathol. 2009 Mar;28(2):179-86
pubmed: 19188815
Expert Rev Mol Diagn. 2004 Mar;4(2):157-67
pubmed: 14995903
Mol Cell Endocrinol. 2003 Apr 28;202(1-2):97-9
pubmed: 12770737
J Control Release. 2015 Oct 10;215:39-54
pubmed: 26220617
Exp Ther Med. 2018 Jul;16(1):73-82
pubmed: 29896229
Clin Exp Metastasis. 2008;25(6):643-55
pubmed: 18398687
Oncol Lett. 2019 Jul;18(1):22-28
pubmed: 31289467
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Lab Invest. 2013 May;93(5):528-42
pubmed: 23459371
Nat Commun. 2014;5:3156
pubmed: 24448499
Oncotarget. 2014 Jan 30;5(2):544-60
pubmed: 24504219
BMC Cancer. 2019 Aug 22;19(1):829
pubmed: 31438892
Int J Oncol. 2017 Dec;51(6):1887-1897
pubmed: 29039611
Cancer Res. 2006 Feb 1;66(3):1526-35
pubmed: 16452209
J Cell Physiol. 2017 Feb;232(2):391-401
pubmed: 27198989
Neoplasia. 2017 Jul;19(7):549-563
pubmed: 28601643
Ann Oncol. 2016 Aug;27(8):1449-55
pubmed: 27037296
Cancer. 2005 Dec 15;104(12):2807-16
pubmed: 16284991
Biomicrofluidics. 2013 Jan 10;7(1):11805
pubmed: 24403987
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110